×
About 2,033 results

ALLMedicine™ Hyperphosphatemia Center

Research & Reviews  683 results

Novel intestinal dialysis interventions and microbiome modulation to control uremia.
https://doi.org/10.1097/MNH.0000000000000753 10.1093/ndt/gfaa205. 10.1111/1744-9987.13707.
Current Opinion in Nephrology and Hypertension; Sumida K, Lau WL et. al.

Dec 1st, 2021 - In patients with chronic kidney disease (CKD), the gut plays a key role in the homeostasis of fluid and electrolyte balance and the production and disposal of uremic toxins. This review summarizes the current evidence on the gut-targeted intervent...

Lack of GNAS re-methylation during oogenesis may be a cause of sporadic pseudohypoparat...
https://doi.org/10.1210/clinem/dgab830
The Journal of Clinical Endocrinology and Metabolism; Milioto A, Reyes M et. al.

Nov 19th, 2021 - Pseudohypoparathyroidism type Ib (PHP1B) is characterized by hypocalcemia and hyperphosphatemia due to PTH-resistance in the proximal renal tubules. Maternal pathogenic STX16/GNAS variants leading to maternal epigenetic GNAS changes impair express...

Regulation of FGF23: Beyond Bone.
https://doi.org/10.1007/s11914-021-00703-w
Current Osteoporosis Reports; Simic P, Babitt JL

Nov 11th, 2021 - Fibroblast growth factor 23 (FGF23) is a bone- and bone marrow-derived hormone that is critical to maintain phosphate homeostasis. The principal actions of FGF23 are to reduce serum phosphate levels by decreasing kidney phosphate reabsorption and ...

Activation of the Calcium Receptor by Calcimimetic Agents is Preserved Despite Modest A...
https://doi.org/10.1681/ASN.2021060825
Journal of the American Society of Nephrology : JASN; Goodman W, Ward D et. al.

Nov 5th, 2021 - Background Some reports indicate that serum phosphorus levels in the range seen clinically among patients undergoing dialysis attenuate calcium receptor activation and modify parathyroid hormone (PTH) release from isolated parathyroid glands in vi...

see more →

Drugs  14 results see all →

Clinicaltrials.gov  36 results

Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical Surgery
https://clinicaltrials.gov/ct2/show/NCT04294277

Aug 16th, 2021 - This is an open-label, single-arm, Phase II study, evaluating safety and efficacy of INCB054828 (Pemigatinib) as adjuvant therapy for molecularly-selected, high-risk patients with urothelial carcinoma (UC) who have received radical surgery. Patien...

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis
https://clinicaltrials.gov/ct2/show/NCT03984760

Mar 10th, 2021 - This is a multicenter, randomized, open-label, active-controlled, parallel, phase III study which aims to assess the efficacy and safety of ferric citrate capsules for the treatment of hyperphosphatemia in patients with chronic kidney disease unde...

Velphoro and Impact on the Oral Cavity and Gut Microbiome
https://clinicaltrials.gov/ct2/show/NCT03409757

Nov 25th, 2020 - The aim of this study is to investigate potential changes in the microbiome of the oral cavity and/or gut in patients with hyperphosphatemia following Velphoro® intake for one month. The principal intention of this study is to assess consequences ...

QoL and Cognitive Function in Patients With Hypoparathyroidism
https://clinicaltrials.gov/ct2/show/NCT04569604

Sep 30th, 2020 - Hypoparathyroidism (HypoPT) is a disease with inadequate production of parathyroid hormone (PTH) from the parathyroid glands leading to hypocalcemia. The most common form is postsurgical HypoPT due to neck surgery resulting in removed or damaged p...

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
https://clinicaltrials.gov/ct2/show/NCT03427125

Aug 25th, 2020 - The study consists of a screening visit, a phosphate binder-free washout period of up to 4 weeks, a 26-week treatment period, an up to 12-week placebo-controlled, randomized withdrawal period, during which patients are randomized 1:1 to either rem...

see more →

News  80 results

Infigratinib Represents New Option for FGFR2+ Cholangiocarcinoma, as Efforts Shift to Target Other FGFR Alterations
https://www.onclive.com/view/infigratinib-represents-new-option-for-fgfr2-cholangiocarcinoma-as-efforts-shift-to-target-other-fgfr-alterations

Nov 9th, 2021 - Infigratinib (Truseltiq) represents a strong option for previously treated patients with locally advanced or metastatic cholangiocarcinoma whose tumors harbor FGFR2 fusions or rearrangements, according to Sameek Roychowdhury, MD, PhD, who added th...

Partner Perspectives: Moving Cholangiocarcinoma Into the Age of Targeted Therapy
https://www.onclive.com/view/partner-perspectives-moving-cholangiocarcinoma-into-the-age-of-targeted-therapy

Oct 6th, 2021 - Biliary tract cancers are an aggressive group of malignancies that historically have been very challenging to treat because of their anatomical location and limited responsiveness to systemic therapy.1-3 Biliary cancers arise from the epithelial l...

TPX-0046 Showcases Early Clinical Activity in RET-Driven Advanced Solid Tumors
https://www.onclive.com/view/tpx-0046-showcases-early-clinical-activity-in-ret-driven-advanced-solid-tumors

Oct 6th, 2021 - The RET inhibitor TPX-0046 demonstrated encouraging preliminary activity, which included objective responses, and an acceptable toxicity profile when used in patients with RET-driven advanced solid tumors, according to data from the phase 1/2 SWOR...

FDA Rejects Tenapanor for Control of Phosphorus in Kidney Disease
https://www.medscape.com/viewarticle/956066

Aug 5th, 2021 - The US Food and Drug Administration (FDA) is asking for an additional clinical trial to demonstrate greater benefits of tenapanor before it can decide on approval of the drug for the control of serum phosphorus in adults with chronic kidney diseas...

Finding the Golden Ticket in Cholangiocarcinoma: Entering the Era of Precision Medicine
https://www.onclive.com/view/finding-the-golden-ticket-in-cholangiocarcinoma-entering-the-era-of-precision-medicine

May 10th, 2021 - The highly heterogeneous nature of cholangiocarcinoma at the genomic, epigenetic, and molecular levels has led to the development of effective new treatments for patients with these rare malignant tumors. Cholangiocarcinoma, the second most common...

see more →